Targeted Neurodegeneration Emerging discovery stage biopharma focusing on neurodegenerative pathways for precision therapeutics and biomarkers, presenting a potential for collaboration on biomarker validation, diagnostic tests, and companion assays.

Single-Cell Genomics Active work on advancing NextGen sequencing at the single-cell level, offering opportunities to supply sequencing reagents, platforms, or service partnerships for high-resolution profiling and biomarker discovery programs.

Strategic Partnerships Part of the D&D Pharmatech/Neuraly ecosystem with ties to leading medical research institutions, indicating openings for joint research programs, grant collaborations, and access to broader academic networks.

Funding and Revenue Profile Current funding of around $13M and revenue in the mid-range, suggesting readiness for early-stage collaborations, pilot studies, and proof-of-concept projects that de-risk larger partnerships.

Technology & Compliance Stack Uses modern digital infrastructure (Squarespace, Commerce tools, Microsoft 365) indicating a lean, web-enabled outreach model; potential upsell for data management systems, collaboration platforms, and compliant data-sharing solutions tailored to biotech startups.